RRC ID 74441
著者 Machado A, Pereira I, Silva V, Pires I, Prada J, Poeta P, Costa L, Pereira JE, Gama M.
タイトル Injectable hydrogel as a carrier of vancomycin and a cathelicidin-derived peptide for osteomyelitis treatment.
ジャーナル J Biomed Mater Res A
Abstract A local drug delivery system that attempts to find a suitable balance between antimicrobial and regenerative actions was developed for osteomyelitis treatment (OM). This system combines the angiogenic and immunomodulatory peptide LLKKK18 (LL18) and vancomycin hydrochloride (VH), loaded into an injectable oxidized dextrin (ODEX)-based hydrogel (HG). In vitro cytotoxicity was analyzed in MC3T3-E1 pre-osteoblasts and erythrocytes. The kinetics of LL18 release was studied. Antimicrobial activity was assessed in vitro against a clinical Methicillin-Resistant Staphylococcus aureus (MRSA) strain. A rat model of acute OM was developed by direct inoculation into a tibia defect, concomitantly with the implantation of the drug-loaded HG. The local bioburden was quantified and damage in surrounding tissues was examined histologically. In vitro, ODEX-based HG displayed a safe hemolytic profile. Half of LL18 (53%) is released during the swelling phase at physiological pH, then being gradually released until complete HG degradation. LL18-loaded HG at 300 μM was the most effective peptide formulation in decreasing in vivo infection among concentrations ranging from 86 to 429 μM. The histopathological scores observed in vivo varied with the LL18 concentration in a dose-dependent manner. VH at 28 mM completely eradicated bacteria, although with substantial tissue injury. We have found that sub-millimolar doses of VH combined with LL18 at 300 μM may suffice to eradicate the infection, with reduced tissue damage. We propose an easy-to-handle, shape-fitting HG formulation with the potential to treat MRSA-infected bone with low VH doses associated with LL18.
巻・号 110(11)
ページ 1786-1800
公開日 2022-11-1
DOI 10.1002/jbm.a.37432
PMID 36082973
MeSH Animals Anti-Bacterial Agents / pharmacology Anti-Bacterial Agents / therapeutic use Antimicrobial Cationic Peptides / pharmacology Antimicrobial Cationic Peptides / therapeutic use Cathelicidins Drug Carriers Hydrogels* / pharmacology Hydrogels* / therapeutic use Methicillin-Resistant Staphylococcus aureus* / metabolism Osteomyelitis* / microbiology Rats Staphylococcal Infections* / drug therapy Staphylococcal Infections* / pathology Vancomycin* / pharmacology Vancomycin* / therapeutic use
IF 3.525
リソース情報
ヒト・動物細胞 MC3T3-E1(RCB1126)